LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice

Rekrutierend

NCT-Nummer:
NCT04733430

Studienbeginn:
April 2020

Letztes Update:
18.03.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Lung Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Karl Landsteiner Institute for Lung Research and Pneumological Oncology

Collaborator:
-

Studienleiter

Georg-Christian Funk, MD
Principal Investigator
2nd Medical Department with Pneumology

Kontakt

Georg-Christian Funk, MD
Kontakt:
Phone: +43 1 4000-2203
E-Mail: georg-christian.funk@gesundheitsverbund.at» Kontaktdaten anzeigen

Agnes Attoh, BSc
Kontakt:
Phone: +43 1 4000-72203
E-Mail: agnes.attoh@extern.gesundheitsverbund.at» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie
1160 Vienna
AustriaRekrutierend» Google-Maps
Ansprechpartner:
Georg-Christian Funk, MD
Phone: +4314000-2203
E-Mail: georg-christian.funk@gesundheitsverbund.at

Agnes Attoh
Phone: +4314000-72203
E-Mail: agnes.attoh@extern.gesundheitsverbund.at» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

The identification of driver-mutations, whose gene product can be specifically inhibited by

targeted therapies, has markedly changed the diagnostic and therapeutic landscape for this

tumor entity, leading to improved outcomes for patients with metastatic NSCLC.

The use of next generation sequencing (NGS) allows for detection of a multitude of different

druggable mutations. In absence of a curative treatment approach and a druggable mutation the

prognosis of lung cancer remains poor.

Thorough knowledge of the treatment reality, e.g. characteristics, diagnostic, treatment and

outcome of unselected patients in real-Iife practice, is crucial to evaluate and improve the

quality of care for patients with lung cancer.

The purpose of this project is to set up a clinical platform to document representative data

on molecular testing, sequence of systemic treatment and other treatment modalities, and

course of disease in patients with lung cancer. A particular focus is on molecular biomarker

testing and NGS of patients before the start of first-line treatment. The data shall be used

to assess the current state of care and to develop recommendations concerning topics that can

be improved.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Informed consent

- Histologically confirmed lung cancer

- Age ≥ 18 years

- Able to understand and willing to sign written Informed Consent and to complete

patient-reported-outcome assessment instruments

Exclusion Criteria:

-

Studien-Rationale

Primary outcome:

1. NGS Testing (Time Frame - through study completion, an average of 5 years):
To assess molecular biomarker testing and indicators of the quality of care in patients with lung cancer

Quelle: ClinicalTrials.gov